3360 trade ideas
HEPA - Bullish DivergencePrice has continued to make lower lows on the monthly, while the stoch & MACD indicators have continue to rise, which should imply bullish divergence. Interested to see how it plays out.
If you assume price will hit the kijun-sen on the ichi moku before rejecting thats a ~1080 point movement.
$HEPA LongHigher low printed at the end of a long downtrend, tested diagonal resistance 3x already. Decent volume. 15% of the company purchased recently as well as insider buys. will be looking for breakout this week. Ideally not a short term trade, hope to be able to hold these shares for a while
Hepion Pharma buy opportunityBuy at market price with stop loss at 1,5 and targets as resistance levels to scale out of your positions.
HEPA LONGThis is an incredible long opportunity, the stock shows huge institutional interest, while also being hugely oversold, combined with the recent breakout. this is exactly what I have been waiting for, this has an outstanding risk to reward ratio.
Call option in progress Strike price @ 2.5
Anything below 1.95 cover your loss .
Good luck and happy holidays!
$HEPA aiming to trade higher-HEPA technical analysis$HEPA Breakout of the wedge:
- RSI divergence.
- MACD looks good.
- Price projection gives 40% possible profits.
- It would saver if traded until $3.81 resistance.
- Patient traders can wait for a pullback for a better entry position.
You can check my ideas here:
notrustyourbroker.com
HEPAprice is creating fast upside want to test Feb consolidation at 5 and maybe reach for something more
$HEPA Alert set for break above $4.50 in Hepion Pharma
First move above 200ma in 4 months produced a
45% move. Alert is set tomorrow for a break above
$4.50 for possible continuation.
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.
HEPION PHARMACEUTICALS INCNASDAQ:HEPA
Another candidate for shorts today.
On March 10, a long-time retest of a strong historical level 2.0. It was formed on 15.08.2019.
From 10.2019 till 27.11.2019 a large long player was gaining a position, which he realized with a gap that day.
The day before yesterday we tested the level, but failed to break it. For the last three days we have been forming a pressure and a set of positions by a short player who needs a big volume to break through the level.
Judging by the price's squeezing to the level, there could be a breakout today.
My entry point is a break-down pattern: 1.98.
Risk Size: 0.07
SL-order I hide up the level after the breakdown.
I exit at a calculated profit of 0.22
My mathematical TP\R ratio is 3.1\1
Important! if you are trading a "rebound-level model" after the breakdown, you should wait for the price to fix under the level. This is a completely different trading model and different logic. Be attentive to what you see on the chart, how the price behaves, and what is written in your trading system. As you understand, 3 different traders can trade 3 different strategies here: a breakout short like me: when I wait for strong small movement enough to get 3.1\1 ratio, a false breakout and long and a "rebound-level model" after the breakdown the level. And all 3 traders will be right.
$HEPA Hepion Pharma could be a mover Tuesday EDISON, NJ / ACCESSWIRE / January 6, 2020 / Hepion Pharmaceuticals, Inc. (HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that the peer-reviewed journal, Expert Opinion on Investigational Drugs, has published a paper entitled, "Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis." Cyclophilins are a family of modulatory enzymes and the target of Hepion's candidate drug, CRV431.
Authored by Hepion's Chief Scientific Officer, Dr. Daren Ure; Senior Vice President of Drug Development, Dr. Daniel Trepanier; Senior Vice President of Clinical Pharmacology, Dr. Patrick Mayo; and CEO, Dr. Robert Foster, the paper is a comprehensive review of studies that have investigated cyclophilins in NASH and NASH-related liver disease. The scientific literature provides abundant evidence that pharmacologic inhibition of cyclophilins with compounds such as Hepion's CRV431 could help to resolve multiple pathophysiological activities that occur in NASH, including mitochondrial dysfunction, liver cell death, inflammation, and most notably, fibrotic scarring of the liver. Targeting several disease processes together is considered the most effective way to treat NASH.
"We believe the invitation to submit this seminal publication recognizes our team's collective 100+ years of cyclophilin research and drug discovery, and the growing appreciation that this class of drug offers therapeutic opportunities that other NASH drug candidates do not," said Dr. Foster.
Lead author, Dr. Ure, further commented, "Decades of research, especially in other fields such as cardiology and neurology, have defined roles for cyclophilins in the most fundamental and universal of disease mechanisms. Applying that knowledge now to liver disease represents a novel and compelling approach in the development of new drug treatments for NASH."
